Jennifer Amengual – New Associate Editor for Blood Neoplasia!
Blood Journals Portfolio shared on LinkedIn:
”We are delighted to introduce Dr. Jennifer Amengual, new Associate Editor for Blood Neoplasia!
Dr. Amengual is an Associate Professor of Medicine at Columbia University Irving Medical Center and a physician-scientist whose research focuses on developing targeted therapies for patients with lymphoma.
Her work has advanced our understanding of epigenetic and transcriptional pathways in germinal center–derived B-cell and T-cell lymphomas, as well as strategies to predict, prevent, and treat post-transplant lymphoproliferative disorders.
Beyond her research, Dr. Amengual is a dedicated mentor and an active member of American Society of Hematology, contributing to programs such as CRTI, TRTH, and the Hematology Review Series.
She has also led impactful clinical trials through ETCTN/CTEP, SWOG, and investigator-initiated studies.
Please join us in welcoming Dr. Amengual to the Blood Neoplasia team.”
Stay updated with Hemostasis Today.
-
Apr 13, 2026, 17:41Peter Zdziarski: Glanzmann’s Research Foundation Listed as GT Patient Organization on NORD
-
Apr 13, 2026, 17:39Nathan Connell: Why Prophylaxis in vWD Has Historically Lagged Behind Established Practice in Hemophilia
-
Apr 13, 2026, 17:38Tareq Abadl: A Blood Transfusion Can Cause a Delayed Platelet Crash
-
Apr 13, 2026, 13:33Tetsumei Urano: Join for the ISTH Educational Programs at APSTH 2026 in Japan
-
Apr 13, 2026, 13:26Salih Ehsan: Neutrophil Behavior Across Pregnancy and Infection Assessment
-
Apr 13, 2026, 13:20Denis Oduor: Autologous Blood Transfusion – A Significant Moment in Patient Care and Choice
-
Apr 13, 2026, 13:13Tareq Abadl: How the Immune System Turns Against the Body in Autoimmune Diseases
-
Apr 13, 2026, 13:13Yousra Tera: Celebrating a Lasting Impact on Future Generations
-
Apr 13, 2026, 13:07Laura Dormer: Real-World Insights into Treatment and Costs in VWD from FORvWARD Study